Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)
NCT ID: NCT00704951
Last Updated: 2015-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2008-07-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)
NCT00686621
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
NCT00811642
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
NCT00034632
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
NCT00034671
A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)
NCT00550732
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
Posaconazole or alternative fungal treatment
Dosage of Posaconazole:
Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Posaconazole or alternative fungal treatment
Dosage of Posaconazole:
Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients eligible for prophylactic treatment due to anticipated neutropenia for more than 7 days.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P05532
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.